Cite
MLA Citation
Iordanis Gravanis et al.. “The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.” Oncologist, vol. 21, 2016, pp. 102–109. http://access.bl.uk/ark:/81055/vdc_100054334469.0x000025